Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Wang, Yonggang ^a,b   Miao, Xiao ^b,c   Liu, Yucheng ^b   Li, Fengsheng ^b,d   Liu, Quan ^a   Sun, Jian ^a   Cai, Lu ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d Second Artillery General Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; AMINO ACIDS; CELL DEATH; DISEASES; PATHOLOGY;

CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; HISTONE ACETYLATION; HISTONE ACETYLTRANSFERASES; HYPERTENSION , PULMONARY; POST-TRANSCRIPTIONAL MODIFICATION; REVERSIBLE ACETYLATION;

PROTEINS;

ALPHA ACTININ; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; ENDOTHELIN 1; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE H3; HISTONE H4; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; MYOCYTE ENHANCER FACTOR 2; MYOSIN HEAVY CHAIN BETA; PLATELET DERIVED GROWTH FACTOR; SERUM RESPONSE FACTOR; SIRTUIN; SOMATOMEDIN RECEPTOR; TRANSCRIPTION FACTOR; VASCULOTROPIN; ZINC FINGER PROTEIN;

ACETYLATION; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHROMATIN; CORONARY ARTERY DISEASE; DIABETIC CARDIOMYOPATHY; ENZYME REGULATION; FIBROSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HISTONE ACETYLATION; HUMAN; HYPERTENSION; INFLAMMATION; MUSCLE CELL; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PULMONARY HYPERTENSION; REVIEW; ANIMAL; ENZYMOLOGY; METABOLISM; PATHOLOGY; TRANSLATIONAL RESEARCH;

ACETYLATION; ANIMALS; CARDIOVASCULAR DISEASES; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84896289692     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/641979     Document Type: Review

References (114)

1. Cohn J. N., Ferrari R., Sharpe N., Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Journal of the American College of Cardiology 2000 35 3 569 582 2-s2.0-0034162004 10.1016/S0735-1097(99)00630-0 (Pubitemid 30167013)
2. Gupta M. P., Samant S. A., Smith S. H., Shroff S. G., HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity. The Journal of Biological Chemistry 2008 283 15 10135 10146 2-s2.0-44349184388 10.1074/jbc.M710277200
3. Samant S. A., Courson D. S., Sundaresan N. R., Pillai V. B., Tan M., Zhao Y., Shroff S. G., Rock R. S., Gupta M. P., HDAC3-dependent reversible lysine acetylation of cardiac myosin heavy chain isoforms modulates their enzymatic and motor activity. The Journal of Biological Chemistry 2011 286 7 5567 5577 2-s2.0-79953133501 10.1074/jbc.M110.163865
4. Sharov V. G., Sabbah H. N., Shimoyama H., Goussev A. V., Lesch M., Goldstein S., Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. The American Journal of Pathology 1996 148 1 141 149 2-s2.0-0030048713 (Pubitemid 26019652)
5. Weber K. T., Pick R., Silver M. A., Moe G. W., Janicki J. S., Zucker I. H., Armstrong P. W., Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 1990 82 4 1387 1401 2-s2.0-0025534384
6. Iyer A., Fenning A., Lim J., Le G. T., Reid R. C., Halili M. A., Fairlie D. P., Brown L., Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. British Journal of Pharmacology 2010 159 7 1408 1417 2-s2.0-77949794821 10.1111/j.1476-5381.2010.00637.x
7. Kee H. J., Sohn I. S., Nam K. I., Park J. E., Qian Y. R., Yin Z., Ahn Y., Jeong M. H., Bang Y.-J., Kim N., Kim J.-K., Kim K. K., Epstein J. A., Kook H., Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006 113 1 51 59 2-s2.0-33644861578 10.1161/CIRCULATIONAHA.105.559724 (Pubitemid 43958488)
8. Jain S., Wei J., Mitrani L. R., Bishopric N. H., Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival. Breast Cancer Research and Treatment 2012 135 1 103 114 2-s2.0-84860549975 10.1007/s10549-012-2069-6
9. Cao D. J., Wang Z. V., Battiprolu P. K., Jiang N., Morales C. R., Kong Y., Rothermel B. A., Gillette T. G., Hill J. A., Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proceedings of the National Academy of Sciences of the United States of America 2011 108 10 4123 4128 2-s2.0-79952775153 10.1073/pnas.1015081108
10. McKinsey T. A., Targeting inflammation in heart failure with histone deacetylase inhibitors. Molecular Medicine 2011 17 5-6 434 441 2-s2.0-79957964666 10.2119/molmed.2011.00022
11. Montgomery R. L., Potthoff M. J., Haberland M., Qi X., Matsuzaki S., Humphries K. M., Richardson J. A., Bassel-Duby R., Olson E. N., Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. The Journal of Clinical Investigation 2008 118 11 3588 3597 2-s2.0-55849084700 10.1172/JCI35847
12. Berger S. L., Kouzarides T., Shiekhattar R., Shilatifard A., An operational definition of epigenetics. Genes & Development 2009 23 7 781 783 2-s2.0-64349095390 10.1101/gad.1787609
13. Lee H. A., Lee D. Y., Cho H. M., Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension. Circulation Research 2013 112 7 1004 1012 10.1161/CIRCRESAHA.113.301071
14. Mu S. Y., Shimosawa T., Ogura S., Wang H., Uetake Y., Kawakami-Mori F., Marumo T., Yatomi Y., Geller D. S., Tanaka H., Fujita T., Epigenetic modulation of the renal β -adrenergic-WNK4 pathway in salt-sensitive hypertension. Nature Medicine 2011 17 5 573 580 10.1038/nm.2337
15. Vadvalkar S. S., Baily C. N., Matsuzaki S., Metabolic inflexibility and protein lysine acetylation in heart mitochondria of a chronic model of Type 1 diabetes. The Biochemical Journal 2013 449 1 253 261 10.1042/BJ20121038
16. Thal M. A., Krishnamurthy P., Mackie A. R., Enhanced angiogenic and cardiomyocyte differentiation capacity of epigenetically reprogrammed mouse and human endothelial progenitor cells augments their efficacy for ischemic myocardial repair. Circulation Research 2012 111 2 180 190 10.1161/CIRCRESAHA. 112.270462
17. Soubrier F., Chung W. K., Machado R., Genetics and genomics of pulmonary arterial hypertension. Journal of the American College of Cardiology 2013 62 25, supplement D13 D21 10.1016/j.jacc.2013.10.035
18. Yang Q., Lu Z., Ramchandran R., Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude long-term hypoxia: role of histone acetylation. American Journal of Physiology 2012 303 11 L1001 L1010 10.1152/ajplung.00092.2012
19. Tang Y., Boucher J. M., Liaw L., Histone deacetylase activity selectively regulates notch-mediated smooth muscle differentiation in human vascular cells. Journal of the American Heart Association 2012 1 3 e000901 10.1161/JAHA.112. 000901
20. Liu Y., Wang Z., Wang J., A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor- β and vascular endothelial growth factor signalling. Liver International 2013 33 4 504 515 10.1111/liv.12034
21. Allfrey V. G., Pogo B. G. T., Littau V. C., Gershey E. L., Mirsky A. E., Histone acetylation in insect chromosomes. Science 1968 159 3812 314 316 2-s2.0-0014422516
22. Yang X.-J., Seto E., Lysine acetylation: codified crosstalk with other posttranslational modifications. Molecular Cell 2008 31 4 449 461 2-s2.0-49349107518 10.1016/j.molcel.2008.07.002
23. Blander G., Guarente L., The Sir2 family of protein deacetylases. Annual Review of Biochemistry 2004 73 417 435 2-s2.0-3943054839 10.1146/annurev. biochem.73.011303.073651 (Pubitemid 39050375)
24. Cheung W. L., Briggs S. D., Allis C. D., Acetylation and chromosomal functions. Current Opinion in Cell Biology 2000 12 3 326 333 2-s2.0-0034020466 10.1016/S0955-0674(00)00096-X (Pubitemid 30265062)
25. Yang X.-J., Seto E., HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007 26 37 5310 5318 2-s2.0-34547924046 10.1038/sj.onc.1210599 (Pubitemid 47255917)
26. Kim Y. S., Kim M. J., Koo T. H., Histone deacetylase is required for the activation of Wnt/ β -catenin signaling crucial for heart valve formation in zebrafish embryos. Biochemical and Biophysical Research Communications 2012 423 1 140 146 10.1016/j.bbrc.2012.05.098
27. Brown C. E., Lechner T., Howe L., Workman J. L., The many HATs of transcription coactivators. Trends in Biochemical Sciences 2000 25 1 15 19 2-s2.0-0033985079 10.1016/S0968-0004(99)01516-9 (Pubitemid 30060424)
28. Parthun M. R., Widom J., Gottschling D. E., The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism. Cell 1996 87 1 85 94 2-s2.0-0030271392 10.1016/S0092-8674(00)81325-2 (Pubitemid 26337393)
29. Burgess R. J., Zhou H., Han J., Zhang Z., A role for Gcn5 in replication-coupled nucleosome assembly. Molecular Cell 2010 37 4 469 480 2-s2.0-76849084692 10.1016/j.molcel.2010.01.020
30. Sklenar A. R., Parthun M. R., Characterization of yeast histone H3-specific type B histone acetyltransferases identifies an ADA2-independent Gcn5p activity. BMC Biochemistry 2004 5, article 11 10.1186/1471-2091-5-11
31. Yang X., Yu W., Shi L., Sun L., Liang J., Yi X., Li Q., Zhang Y., Yang F., Han X., Zhang D., Yang J., Yao Z., Shang Y., HAT4, a golgi apparatus-anchored B-type histone acetyltransferase, acetylates free histone H4 and facilitates chromatin assembly. Molecular Cell 2011 44 1 39 50 2-s2.0-80053609229 10.1016/j.molcel.2011.07.032
32. Yao T.-P., Oh S. P., Fuchs M., Zhou N.-D., Ch'ng L.-E., Newsome D., Bronson R. T., Li E., Livingston D. M., Eckner R., Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998 93 3 361 372 2-s2.0-17644445419 10.1016/S0092-8674(00)81165-4 (Pubitemid 28232081)
33. Shikama N., Lutz W., Kretzschmar R., Sauter N., Roth J.-F., Marino S., Wittwer J., Scheidweiler A., Eckner R., Essential function of p300 acetyltransferase activity in heart, lung and small intestine formation. The EMBO Journal 2003 22 19 5175 5185 2-s2.0-0141753974 10.1093/emboj/cdg502 (Pubitemid 37222037)
34. Majumdar G., Adris P., Bhargava N., Pan-histone deacetylase inhibitors regulate signaling pathways involved in proliferative and pro-inflammatory mechanisms in H9c2 cells. BMC Genomics 2012 13, article 709 10.1186/1471-2164- 13-709
35. Zhang L., Qin X., Zhao Y., Fast L., Zhuang S., Liu P., Cheng G., Zhao T. C., Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis. The Journal of Pharmacology and Experimental Therapeutics 2012 341 1 285 293 2-s2.0-84858645117 10.1124/jpet.111.189910
36. Mosashvilli D., Kahl P., Mertens C., Holzapfel S., Rogenhofer S., Hauser S., Büttner R., Von Ruecker A., Müller S. C., Ellinger J., Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Science 2010 101 12 2664 2669 2-s2.0-78449274443 10.1111/j.1349-7006.2010.01717.x
37. Elsheikh S. E., Green A. R., Rakha E. A., Powe D. G., Ahmed R. A., Collins H. M., Soria D., Garibaldi J. M., Paish C. E., Ammar A. A., Grainge M. J., Ball G. R., Abdelghany M. K., Martinez-Pomares L., Heery D. M., Ellis I. O., Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Research 2009 69 9 3802 3809 2-s2.0-65949086183 10.1158/0008-5472.CAN-08-3907
38. Ceccatelli S., Bose R., Edoff K., Long-lasting neurotoxic effects of exposure to methylmercury during development. Journal of Internal Medicine 2013 273 5 490 497 10.1111/joim.12045
39. McFarland K. N., Das S., Sun T. T., Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease. PloS ONE 2012 7 7 e41423 0.1371/journal.pone.0041423
40. Norman R. E., Carpenter D. O., Scott J., Environmental exposures: an underrecognized contribution to noncommunicable diseases. Reviews on Environmental Health 2013 28 1 59 65 10.1515/reveh-2012-0033
41. Xu Q., Lin X., Andrews L., Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication. Frontiers in Pharmacology 2013 4, article 44 10.3389/fphar.2013.00044
42. Xie M., Hill J. A., HDAC-dependent ventricular remodeling. Trends in Cardiovascular Medicine 2013 23 6 229 235 10.1016/j.tcm.2012.12.006
43. Cardinale J. P., Sriramula S., Pariaut R., Guggilam A., Mariappan N., Elks C. M., Francis J., HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010 56 3 437 444 2-s2.0-77955984513 10.1161/HYPERTENSIONAHA.110.154567
44. Lacolley P., Regnault V., Nicoletti A., The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovascular Research 2012 95 2 194 204 10.1093/cvr/cvs135
45. Xu X., Ha C.-H., Wong C., Wang W., Hausser A., Pfizenmaier K., Olson E. N., McKinsey T. A., Jin Z.-G., Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 11 2355 2362 2-s2.0-36049028271 10.1161/ATVBAHA.107. 151704 (Pubitemid 350203950)
46. Li H., Li W., Gupta A. K., Mohler P. J., Anderson M. E., Grumbach I. M., Calmodulin kinase II is required for angiotensin II-mediated vascular smooth muscle hypertrophy. American Journal of Physiology 2010 298 2 H688 H698 2-s2.0-74949099401 10.1152/ajpheart.01014.2009
47. Okada M., Usui T., Mizuno W., Oda M., Ide N., Morita T., Hara Y., Yamawaki H., HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats. American Journal of Physiology 2012 302 9 H1894 H1904 2-s2.0-84860529747 10.1152/ajpheart.01039.2011
48. Kim G. H., Ryan J. J., Marsboom G., Epigenetic mechanisms of pulmonary hypertension. Pulmonary Circulation 2011 1 3 347 356 10.4103/2045-8932.87300
49. Xu X. F., Lv Y., Gu W. Z., Epigenetics of hypoxic pulmonary arterial hypertension following intrauterine growth retardation rat: epigenetics in PAH following IUGR. Respiratory Research 2013 14 1, article 20 10.1186/1465-9921-14- 20
50. Zhao L., Chen C. N., Hajji N., Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012 126 4 455 467
51. Li M., Riddle S. R., Frid M. G., El Kasmi K. C., McKinsey T. A., Sokol R. J., Strassheim D., Meyrick B., Yeager M. E., Flockton A. R., McKeon B. A., Lemon D. D., Horn T. R., Anwar A., Barajas C., Stenmark K. R., Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. The Journal of Immunology 2011 187 5 2711 2722 2-s2.0-80052667354 10.4049/jimmunol.1100479
52. Cavasin M. A., Demos-Davies K., Horn T. R., Walker L. A., Lemon D. D., Birdsey N., Weiser-Evans M. C. M., Harral J., Irwin D. C., Anwar A., Yeager M. E., Li M., Watson P. A., Nemenoff R. A., Buttrick P. M., Stenmark K. R., McKinsey T. A., Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circulation Research 2012 110 5 739 748 2-s2.0-84857815408 10.1161/CIRCRESAHA.111.258426
53. Shimosawa T., Hypertension and its related organ damage-pathophysiology and new diagnostic strategy. The Japanese Journal of Clinical Pathology 2013 61 3 263 270
54. Libby P., Ridker P. M., Hansson G. K., Progress and challenges in translating the biology of atherosclerosis. Nature 2011 473 7347 317 325 2-s2.0-79956319051 10.1038/nature10146
55. Bruchas R. R., de Las Fuentes L., Carney R. M., The St. Louis African American health-heart study: methodology for the study of cardiovascular disease and depression in young-old African Americans. BMC Cardiovascular Disorders 2013 13 1, article 66 10.1186/1471-2261-13-66
56. Reddy M. A., Natarajan R., Epigenetic mechanisms in diabetic vascular complications. Cardiovascular Research 2011 90 3 421 429 2-s2.0-79957487252 10.1093/cvr/cvr024
57. Doran A. C., Meller N., McNamara C. A., Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 5 812 819 2-s2.0-42149107512 10.1161/ATVBAHA.107.159327 (Pubitemid 351544093)
58. Manabe I., Owens G. K., Recruitment of serum response factor and hyperacetylation of histones at smooth muscle-specific regulatory regions during differentiation of a novel P19-derived in vitro smooth muscle differentiation system. Circulation Research 2001 88 11 1127 1134 2-s2.0-0035827729 (Pubitemid 34132512)
59. Cao D., Wang Z., Zhang C.-L., Oh J., Xing W., Li S., Richardson J. A., Wang D.-Z., Olson E. N., Modulation of smooth muscle gene expression by association of histone acetyltransferases and deacetylases with myocardin. Molecular and Cellular Biology 2005 25 1 364 376 2-s2.0-11144250262 10.1128/MCB.25.1.364-376.2005 (Pubitemid 40039826)
60. McDonald O. G., Wamhoff B. R., Hoofnagle M. H., Owens G. K., Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. The Journal of Clinical Investigation 2006 116 1 36 48 2-s2.0-31044442783 10.1172/JCI26505 (Pubitemid 43121789)
61. Choi J.-H., Nam K.-H., Kim J., Baek M. W., Park J.-E., Park H.-Y., Kwon H. J., Kwon O.-S., Kim D.-Y., Oh G. T., Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 11 2404 2409 2-s2.0-27644550272 10.1161/01.ATV.0000184758.07257.88 (Pubitemid 41552662)
62. Lakshmi S. V., Naushad S. M., Reddy C. A., Oxidative stress in coronary artery disease: epigenetic perspective. Molecular and Cellular Biochemistry 2013 374 1-2 203 211 10.1007/s11010-012-1520-7
63. Mangino M., Spector T., Understanding coronary artery disease using twin studies. Heart 2013 99 6 373 375 10.1136/heartjnl-2012-303001
64. Nadtochiy S. M., Redman E., Rahman I., Brookes P. S., Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. Cardiovascular Research 2011 89 3 643 649 2-s2.0-79551470041 10.1093/cvr/cvq287
65. Wierda R. J., Geutskens S. B., Jukema J. W., Quax P. H. A., van den Elsen P. J., Epigenetics in atherosclerosis and inflammation. Journal of Cellular and Molecular Medicine 2010 14 6A 1225 1240 2-s2.0-77955162230 10.1111/j.1582-4934. 2010.01022.x
66. McMurray J. J. V., Pfeffer M. A., Heart failure. The Lancet 2005 365 9474 1877 1889 2-s2.0-19744378213 10.1016/S0140-6736(05)66621-4 (Pubitemid 40744967)
67. Kehat I., Molkentin J. D., Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010 122 25 2727 2735 2-s2.0-78650710691 10.1161/CIRCULATIONAHA.110.942268
68. Gusterson R., Brar B., Faulkes D., Giordano A., Chrivia J., Latchman D., The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade. The Journal of Biological Chemistry 2002 277 4 2517 2524 2-s2.0-0037169542 10.1074/jbc.M104626200 (Pubitemid 34953275)
69. Gusterson R. J., Jazrawi E., Adcock I. M., Latchman D. S., The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. The Journal of Biological Chemistry 2003 278 9 6838 6847 2-s2.0-0037470133 10.1074/jbc.M211762200 (Pubitemid 36800674)
70. Yanazume T., Hasegawa K., Morimoto T., Kawamura T., Wada H., Matsumori A., Kawase Y., Hirai M., Kita T., Cardiac p300 is involved in myocyte growth with decompensated heart failure. Molecular and Cellular Biology 2003 23 10 3593 3606 2-s2.0-0038302887 10.1128/MCB.23.10.3593-3606.2003 (Pubitemid 36539192)
71. Dai Y.-S., Markham B. E., p300 functions as a coactivator of transcription factor GATA-4. The Journal of Biological Chemistry 2001 276 40 37178 37185 2-s2.0-0035813095 10.1074/jbc.M103731200
72. Slepak T. I., Webster K. A., Zang J., Prentice H., O'Dowd A., Hicks M. N., Bishopric N. H., Control of cardiac-specific transcription by p300 through myocyte enhancer factor-2D. The Journal of Biological Chemistry 2001 276 10 7575 7585 2-s2.0-0035831460 10.1074/jbc.M004625200
73. Cao D., Wang C., Tang R., Acetylation of myocardin is required for the activation of cardiac and smooth muscle genes. The Journal of Biological Chemistry 2012 287 46 38495 38504 10.1074/jbc.M112.353649
74. Colussi C., Illi B., Rosati J., Spallotta F., Farsetti A., Grasselli A., Mai A., Capogrossi M. C., Gaetano C., Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacological Research 2010 62 1 3 10 2-s2.0-77952880971 10.1016/j.phrs.2010. 02.014
75. Dingar D., Konecny F., Zou J., Anti-apoptotic function of the E2F transcription factor 4 (E2F4)/p130, a member of retinoblastoma gene family in cardiac myocytes. Journal of Molecular and Cellular Cardiology 2012 53 6 820 828 10.1016/j.yjmcc.2012.09.004
76. Tomita K., Barnes P. J., Adcock I. M., The effect of oxidative stress on histone acetylation and IL-8 release. Biochemical and Biophysical Research Communications 2003 301 2 572 577 2-s2.0-0037423725 10.1016/S0006-291X(02)03029- 2 (Pubitemid 36279279)
77. Dooley R., Harvey B. J., Thomas W., The regulation of cell growth and survival by aldosterone. Frontiers in Bioscience 2011 16 2 440 457 2-s2.0-79955010414 10.2741/3697
78. Planavila A., Dominguez E., Navarro M., Dilated cardiomyopathy and mitochondrial dysfunction in Sirt1-deficient mice: a role for Sirt1-Mef2 in adult heart. Journal of Molecular and Cellular Cardiology 2012 53 4 521 531
79. Vakhrusheva O., Smolka C., Gajawada P., Kostin S., Boettger T., Kubin T., Braun T., Bober E., Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circulation Research 2008 102 6 703 710 2-s2.0-41449083867 10.1161/CIRCRESAHA.107.164558 (Pubitemid 351457857)
80. Chen S. S. H., Jenkins A. J., Majewski H., Elevated plasma prostaglandins and acetylated histone in monocytes in type 1 diabetes patients. Diabetic Medicine 2009 26 2 182 186 2-s2.0-60049100698 10.1111/j.1464-5491.2008.02658.x
81. Paneni F., Mocharla P., Akhmedov A., Gene silencing of the mitochondrial adaptor p66Shc suppresses vascular hyperglycemic memory in diabetes. Circulation Research 2012 111 3 278 289 10.1161/CIRCRESAHA.112.266593
82. Yu X.-Y., Geng Y.-J., Liang J.-L., Lin Q.-X., Lin S.-G., Zhang S., Li Y., High levels of glucose induce apoptosis in cardiomyocyte via epigenetic regulation of the insulin-like growth factor receptor. Experimental Cell Research 2010 316 17 2903 2909 2-s2.0-77956883842 10.1016/j.yexcr.2010.07.004
83. Kee H. J., Kook H., Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. Journal of Biomedicine and Biotechnology 2011 2011 10 2-s2.0-79251588033 10.1155/2011/928326 928326
84. Montgomery R. L., Davis C. A., Potthoff M. J., Haberland M., Fielitz J., Qi X., Hill J. A., Richardson J. A., Olson E. N., Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes & Development 2007 21 14 1790 1802 2-s2.0-34447511648 10.1101/gad.1563807 (Pubitemid 47076478)
85. Trivedi C. M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., Floss T., Goettlicher M., Noppinger P. R., Wurst W., Ferrari V. A., Abrams C. S., Gruber P. J., Epstein J. A., Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 β activity. Nature Medicine 2007 13 3 324 331 2-s2.0-33847695362 10.1038/nm1552 (Pubitemid 46376684)
86. Trivedi C. M., Lu M. M., Wang Q., Epstein J. A., Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. The Journal of Biological Chemistry 2008 283 39 26484 26489 2-s2.0-55549099609 10.1074/jbc.M803686200
87. Singh N., Trivedi C. M., Lu M., Mullican S. E., Lazar M. A., Epstein J. A., Histone deacetylase 3 regulates smooth muscle differentiation in neural crest cells and development of the cardiac outflow tract. Circulation Research 2011 109 11 1240 1249 2-s2.0-81355127622 10.1161/CIRCRESAHA.111.255067
88. Kee H. J., Bae E. H., Park S., HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity. Kidney & Blood Pressure Research 2013 37 4-5 229 239 10.1159/000350148
89. Backs J., Olson E. N., Control of cardiac growth by histone acetylation/deacetylation. Circulation Research 2006 98 1 15 24 2-s2.0-33644837326 10.1161/01.RES.0000197782.21444.8f (Pubitemid 43977219)
90. McKinsey T. A., Zhang C. L., Olson E. N., MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends in Biochemical Sciences 2002 27 1 40 47 2-s2.0-0036165434 10.1016/S0968-0004(01)02031-X (Pubitemid 34131624)
91. Backs J., Song K., Bezprozvannaya S., Chang S., Olson E. N., CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. The Journal of Clinical Investigation 2006 116 7 1853 1864 2-s2.0-33745812011 10.1172/JCI27438 (Pubitemid 44033310)
92. Bush E., Fielitz J., Melvin L., Martinez-Arnold M., McKinsey T. A., Plichta R., Olson E. N., A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 2004 101 9 2870 2875 2-s2.0-1542297759 10.1073/pnas.0308723101 (Pubitemid 38327703)
93. Vega R. B., Harrison B. C., Meadows E., Roberts C. R., Papst P. J., Olson E. N., McKinsey T. A., Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Molecular and Cellular Biology 2004 24 19 8374 8385 2-s2.0-4544315655 10.1128/MCB.24.19. 8374-8385.2004 (Pubitemid 39245060)
94. Ye J., Llorian M., Cardona M., A pathway involving HDAC5, cFLIP and caspases regulates expression of the splicing regulator polypyrimidine tract binding protein in the heart. Journal of Cell Science 2013 126, part 7 1682 1691 10.1242/jcs.121384
95. Zhang C. L., McKinsey T. A., Chang S., Antos C. L., Hill J. A., Olson E. N., Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002 110 4 479 488 2-s2.0-0037162697 10.1016/S0092-8674(02) 00861-9 (Pubitemid 35232291)
96. Chang S., McKinsey T. A., Zhang C. L., Richardson J. A., Hill J. A., Olson E. N., Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Molecular and Cellular Biology 2004 24 19 8467 8476 2-s2.0-4544358659 10.1128/MCB.24.19.8467-8476.2004 (Pubitemid 39245069)
97. Chen L., Endler A., Shibasaki F., Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Experimental & Molecular Medicine 2009 41 12 849 857 2-s2.0-75149157036 10.3858/emm.2009.41.12. 103
98. To M., Yamamura S., Akashi K., Charron C. E., Haruki K., Barnes P. J., Ito K., Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. Chest 2012 141 5 1233 1242 2-s2.0-84860549760 10.1378/chest.11-1536
99. Hunt S. A., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology 2005 46 6 e1 e82 10.1016/j.jacc.2005.08.022 (Pubitemid 41316530)
100. Udali S., Guarini P., Moruzzi S., Cardiovascular epigenetics: from DNA methylation to microRNAs. Molecular Aspects of Medicine 2013 34 4 883 901 10.1016/j.mam.2012.08.001
101. Sundar I. K., Caito S., Yao H., Rahman I., Oxidative stress, thiol redox signaling methods in epigenetics. Methods in Enzymology 2010 474 213 244 2-s2.0-79952728721
102. Ozden O., Park S.-H., Kim H.-S., Jiang H., Coleman M. C., Spitz D. R., Gius D., Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress. Aging 2011 3 2 102 107 2-s2.0-79959541505
103. Di Stefano V., Soddu S., Sacchi A., D'Orazi G., HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p 21Waf1 after nonapoptotic DNA damage. Oncogene 2005 24 35 5431 5442 2-s2.0-24644494726 10.1038/sj.onc.1208717 (Pubitemid 43080087)
104. Bossis G., Melchior F., Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Molecular Cell 2006 21 3 349 357 2-s2.0-31544432283 10.1016/j.molcel.2005.12.019 (Pubitemid 43163530)
105. Yan S., Sun X., Xiang B., Cang H., Kang X., Chen Y., Li H., Shi G., Yeh E. T. H., Wang B., Wang X., Yi J., Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. The EMBO Journal 2010 29 22 3773 3786 2-s2.0-78449275359 10.1038/emboj.2010.245
106. de la Vega L., Grishina I., Moreno R., Krüger M., Braun T., Schmitz M. L., A redox-regulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress. Molecular Cell 2012 46 4 472 483 2-s2.0-84859487764 10.1016/j.molcel.2012.03.003
107. Chen Y., Zhang J., Lin Y., Lei Q., Guan K.-L., Zhao S., Xiong Y., Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Reports 2011 12 6 534 541 2-s2.0-79957979314 10.1038/embor.2011.65
108. Zimmet J. M., Hare J. M., Nitroso-redox interactions in the cardiovascular system. Circulation 2006 114 14 1531 1544 2-s2.0-33749515825 10.1161/CIRCULATIONAHA.105.605519 (Pubitemid 44527009)
109. Ago T., Liu T., Zhai P., Chen W., Li H., Molkentin J. D., Vatner S. F., Sadoshima J., A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 2008 133 6 978 993 2-s2.0-44649184557 10.1016/j.cell.2008.04.041 (Pubitemid 351787743)
110. Matsushima S., Kuroda J., Ago T., Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circulation Research 2013 112 4 651 663 10.1161/CIRCRESAHA.112.279760
111. Wu Q., Xu W., Cao L., SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 cells. Journal of Proteome Research 2013 12 9 4064 4073 10.1021/pr4004079
112. Bossaller L., Rothe A., Monoclonal antibody treatments for rheumatoid arthritis. Expert Opinion on Biological Therapy 2013 13 9 1257 1272
113. Zhang K., Schrag M., Crofton A., Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 2012 12 8 1261 1268
114. Lv L., Tang Y.-P., Han X., Wang X., Dong Q., Therapeutic application of histone deacetylase inhibitors for stroke. Central Nervous System Agents in Medicinal Chemistry 2011 11 2 138 149 2-s2.0-79959287715